Literature DB >> 19399811

Hepatitis B: the virus and disease.

T Jake Liang1.   

Abstract

Hepatitis B virus (HBV) infects more than 300 million people worldwide and is a common cause of liver disease and liver cancer. HBV, a member of the Hepadnaviridae family, is a small DNA virus with unusual features similar to retroviruses. HBV replicates through an RNA intermediate and can integrate into the host genome. The unique features of the HBV replication cycle confer a distinct ability of the virus to persist in infected cells. Virological and serological assays have been developed for diagnosis of various forms of HBV-associated disease and for treatment of chronic hepatitis B infection. HBV infection leads to a wide spectrum of liver disease ranging from acute (including fulminant hepatic failure) to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Acute HBV infection can be either asymptomatic or present with symptomatic acute hepatitis. Most adults infected with the virus recover, but 5%-10% are unable to clear the virus and become chronically infected. Many chronically infected persons have mild liver disease with little or no long-term morbidity or mortality. Other individuals with chronic HBV infection develop active disease, which can progress to cirrhosis and liver cancer. These patients require careful monitoring and warrant therapeutic intervention. Extrahepatic manifestations of HBV infection are rare but can be difficult to diagnose and manage. The challenges in the area of HBV-associated disease are the lack of knowledge in predicting outcome and progression of HBV infection and an unmet need to understand the molecular, cellular, immunological, and genetic basis of various disease manifestations associated with HBV infection.

Entities:  

Mesh:

Year:  2009        PMID: 19399811      PMCID: PMC2809016          DOI: 10.1002/hep.22881

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  61 in total

1.  Internal entry of ribosomes and ribosomal scanning involved in hepatitis B virus P gene expression.

Authors:  O Jean-Jean; T Weimer; A M de Recondo; H Will; J M Rossignol
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

2.  Natural history of woodchuck hepatitis virus infections during the course of experimental viral infection: molecular virologic features of the liver and lymphoid tissues.

Authors:  B E Korba; P J Cote; F V Wells; B Baldwin; H Popper; R H Purcell; B C Tennant; J L Gerin
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

3.  X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo.

Authors:  Z Zhang; N Torii; Z Hu; J Jacob; T J Liang
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication.

Authors:  H E Blum; E Galun; T J Liang; F von Weizsäcker; J R Wands
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

5.  Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers.

Authors:  T J Liang; H E Blum; J R Wands
Journal:  Hepatology       Date:  1990-08       Impact factor: 17.425

Review 6.  Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis.

Authors:  C Trepo; L Guillevin
Journal:  J Autoimmun       Date:  2001-05       Impact factor: 7.094

7.  Membranous nephropathy related to hepatitis B virus in adults.

Authors:  K N Lai; P K Li; S F Lui; T C Au; J S Tam; K L Tong; F M Lai
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

8.  Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen.

Authors:  P Paterlini; G Gerken; E Nakajima; S Terre; A D'Errico; W Grigioni; B Nalpas; D Franco; J Wands; M Kew
Journal:  N Engl J Med       Date:  1990-07-12       Impact factor: 91.245

9.  Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature.

Authors:  C Blanpain; C Knoop; M L Delforge; M Antoine; M O Peny; C Liesnard; P Vereerstraeten; E Cogan; M Adler; D Abramowicz
Journal:  Transplantation       Date:  1998-10-15       Impact factor: 4.939

10.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

View more
  249 in total

Review 1.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

2.  Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.

Authors:  Dawei Cai; Courtney Mills; Wenquan Yu; Ran Yan; Carol E Aldrich; Jeffry R Saputelli; William S Mason; Xiaodong Xu; Ju-Tao Guo; Timothy M Block; Andrea Cuconati; Haitao Guo
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 3.  X region mutations of hepatitis B virus related to clinical severity.

Authors:  Hong Kim; Seoung-Ae Lee; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

4.  Immune mediated crescentic MPGN secondary to HBV infection: A rare presentation for a common infection.

Authors:  Aswani Srinivas Mareddy; Dharshan Rangaswamy; Mahesha Vankalakunti; Ravindra Prabhu Attur; Shankar Prasad Nagaraju; Neeraja Koti
Journal:  Australas Med J       Date:  2016-01-31

5.  Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota.

Authors:  Han-Hsuan Chou; Wei-Hung Chien; Li-Ling Wu; Chi-Hung Cheng; Chen-Han Chung; Jau-Haw Horng; Yen-Hsuan Ni; Hong-Tai Tseng; Dafei Wu; Xuemei Lu; Hurng-Yi Wang; Pei-Jer Chen; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

6.  HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

Authors:  T-W Wu; C-C Chu; H-W Chang Liao; S-K Lin; T-Y Ho; M Lin; H H Lin; L-Y Wang
Journal:  Genes Immun       Date:  2013-11-28       Impact factor: 2.676

7.  Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes.

Authors:  Jan Felix Drexler; Andreas Geipel; Alexander König; Victor M Corman; Debby van Riel; Lonneke M Leijten; Corinna M Bremer; Andrea Rasche; Veronika M Cottontail; Gael D Maganga; Mathias Schlegel; Marcel A Müller; Alexander Adam; Stefan M Klose; Aroldo José Borges Carneiro; Andreas Stöcker; Carlos Roberto Franke; Florian Gloza-Rausch; Joachim Geyer; Augustina Annan; Yaw Adu-Sarkodie; Samuel Oppong; Tabea Binger; Peter Vallo; Marco Tschapka; Rainer G Ulrich; Wolfram H Gerlich; Eric Leroy; Thijs Kuiken; Dieter Glebe; Christian Drosten
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

8.  Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.

Authors:  Scott Bowden; Stephen Locarnini; Ting-Tsung Chang; You-Chen Chao; Kwang-Hyub Han; Robert G Gish; Robert A de Man; Miao Yu; Cyril Llamoso; Hong Tang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

9.  Incorporation of eukaryotic translation initiation factor eIF4E into viral nucleocapsids via interaction with hepatitis B virus polymerase.

Authors:  Seahee Kim; Haifeng Wang; Wang-Shick Ryu
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 10.  HIV/HBV coinfection in children and antiviral therapy.

Authors:  Sara A Healy; Sonia Gupta; Ann J Melvin
Journal:  Expert Rev Anti Infect Ther       Date:  2013-03       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.